Drugs / GRT-R912
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05435027 | Feb 2022 → Mar 2024 | COVID-19 | Gritstone bio, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRT-R912 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05435027 ↗ |
| Known as | samRNA-Spikebeta-TCE11 | “GRT-R912, samRNA-Spikebeta-TCE11” NCT05435027 ↗ |
| Modality | Small activating RNA (saRNA) | “samRNA vaccines GRT-R912, GRT-R914, and GRT-R918” NCT05435027 ↗ |
| Route | Intramuscular | “IM injection of GRT-R912” NCT05435027 ↗ |